Recent advances in colorectal cancer therapy

Cancer Biology and Therapy

Volumn 2, Issue 1, 2003, Pages 5-12

  D'Entremont, Tracy S ^a   Sun, Weijing ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis inhibitors; Antibodies (monoclonal); Antineoplastic agents; Chemotehrapy (adjuvant); Colorectal neoplasms; Cycloxygenase inhibitors; Enzyme inhibitors; Epidermal growth factor; Fluorouacil; Receptor

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL TRIAL; COLORECTAL TUMOR; HUMAN; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS;

EID: 0038159787     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.178     Document Type: Review

References (85)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer Statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49:231-55. (Pubitemid 29525144)
3. Goldberg RM, Fleming TR, Tangem CM, Moertel CG, Macdonald JS, Haller DG, et al. Surgery for recurrent colon cancer: strategies for identifying respectable recurrence and success rates after resection. Ann Inter Med 1998; 129:27-35. (Pubitemid 28304649)
4. DeMatteo RM, Minnard EA, Kemeny N, Downey R, Burt M, Fong Y, et al. Outcome after resection of both liver and lung metastases in patients with colorectal cancer. Proc Am Soc Clin Oncol 1999; 18:249a.
5. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-46. (Pubitemid 27106275)
6. Portier G, Rougier Ph, Milan C, et al. Adjuvant systemic chemotherapy (CT) using 5-fluorouracil (FU) and folinic acid (FA) after resection of liver metastases (LM) from colorectal origin. Results of an intergroup phase III study (trial FFCD-ACHBTH-AURC 9002). Proc Am Soc Clin Oncol 2002; 21:133a.
7. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, et al. Combined-modality treatment for respectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20:1499-505. (Pubitemid 34260528)
8. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Eng J Med 1999; 341:2039-48. (Pubitemid 30035952)
9. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr., Erlichman C, Shepherd L, et al. A prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300. (Pubitemid 28041612)
10. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808-15. (Pubitemid 27074252)
11. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7:425-32. (Pubitemid 19098135)
12. The Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-8.
13. Cohen JL, Irwin LW, Marshall OJ, Darvey H, Bateman JR. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemotherapy Reports 1974; 58:723.
14. Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ, Louis WJ, et al. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clinical Pharmacokinetics 1978; 3:330.
15. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human liver: Population characteristics and clinical implication in 5-FU chemotherapy. Clin Pharmacol Ther 1995; 58:512-22.
16. Daher GC, Harris BE. Metabolism of pyrimidine analogues and their nucleosides, in Powis G (ed): The International Encyclopedia of Pharmacology and Therapeutics. Oxford, Pergamon Press, 1994.
17. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-37. (Pubitemid 19114713)
18. Naguib FNM, El-Kouni MH, Sha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45:5402-12.
19. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-7. (Pubitemid 30151522)
20. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-92. (Pubitemid 32366981)
21. Van Cutsem E, Twelves C, Cassidy J David Allman, Emilio Bajetta, Michael Boyer, et al. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study. J Clin Oncol 2001; 19:4097-106. (Pubitemid 33049527)
22. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991; 83:1164-8.
23. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11:2194-204.
24. Abigerges D, Chabot G, Armand J, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210-21.
25. Cunningham D, Pyrhonen S, James RP, Punt CJ, Hickis TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care verse supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8. (Pubitemid 28510874)
26. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12. (Pubitemid 28510873)
27. Saltz LB, Cox JV, Blanke CB, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Eng J Med 2000; 343:905-14.
28. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041-7. (Pubitemid 30162806)
29. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, florouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:144-5.
30. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 2001; 28 (suppl 1):9-13. (Pubitemid 32173098)
31. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary finding of an independent panel. J Clin Oncol 2001; 19(18):3801-7. (Pubitemid 32880058)
32. Miller L, Emanuel D, Elfring G, Barker K, Saltz L. 60-day, all-cause mortality with firstline irinotecan/fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin (FL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21:129a.
33. Kidani Y, Noji M, Tashiro T. Antitumor activity of platinum(II) complexes of 1,2- diaminocyclohexane isomers. Gann 1980; 71: 637-43. (Pubitemid 10030519)
34. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43:237-50. (Pubitemid 19153975)
35. Jennerwein MM, Eastman A, Khokar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum(II) complexes. Chem Biol Interact 1989; 70: 39.
36. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acid Research 1992; 20:267-72.
37. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9:105-8. (Pubitemid 28125772)
38. Becouarn Y, Ychou M Ducreux M, Borel C, Berthault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16:2739-44. (Pubitemid 28363039)
39. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-8. (Pubitemid 26051870)
40. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Cepres-Brummer P, et al. Oxaliplatin activity against metastatic colorectal cancer. A five-day study of continuous venous infusion at circadian rhythm modulated rate. Eur J Ca 1993; 9:1280-4. (Pubitemid 23169897)
41. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretschmar A, et al. Phase III study of bolus 5-fluoruracil (5-FU)/folinic acid (FA) (mayo) vs. weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:A#512.
42. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16):2938-47. (Pubitemid 30644117)
43. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47. (Pubitemid 30036347)
44. From the food and drug administration. JAMA 2002; 288:1225.
45. Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, et al. N9741: oxaliplatin(oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 2002; 21:128a.
46. Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Pro Am Clin Oncol 2001; 20:124a.
47. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Ca Res 1995; 1:1311-18.
48. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Ca Res 2000; 6:3739-47.
49. Rubin MS, Shin DM, Pasmantier M, Falcey JW, Paulter VJ, Fetzer M, et al. Monoclonal antibody (MoAb) IMC-225, an anti-epidermal growth factor receptor (EGFr) for patients (pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol 2000; 19:474a.
50. Saltz LB, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab plus irinotecan is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001; 20:3a.
51. Schoffski P, Lutz MP, Folprecht G, Beutel G, Seufferlein T, Marschner J-P, et al. Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21: (abst 633).
52. Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E, Ramos L, et al. Erbitux (IMC-225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:536.
53. Ciardiello F, Caputo R, Bianco R, Pomatico G, Damiano V, DePlacido S, et al. Antitumor effects and potentiation of cytotoxic drug activity in human cancer cell lines by ZD-1839 (Iressa ), an EGFR-specific tyrosine kinase inhibitor. Clin Ca Res 1999; 5:3735s.
54. Ciardiello F, Caputo R, Bianco R, Pomatico G, Damiano V, Fontanini G, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Ca Res 2001; 7:1459-65. (Pubitemid 32708703)
55. Baselga J, LoRusso P, Herbst R, Rischin D, Ranson M, Maddox A-M, et al. A pharmacokinetic/ pharmacodynamic trial of ZD1839 (Iressa ), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment). Clin Ca Res 1999; 5:3735s.
56. Ferry D, Hammond L, Ranson M, Kris M, Miller V, Murray P, et al. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKi), shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000; 19:3a.
57. Bergsland E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Gaureault J, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/Leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Clin Oncol 2000; 19:242a.
58. Giantonio B, Levy D, Catalano PJ, O'Dwyer PJ, Benson AB III. Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (ADVCRC): a toxicity analysis of ECOG study E2200. Proc Am Soc Clin Oncol 2002; 21:126a.
59. Blanke CD, Benson AB, Dragovich T, Lenz HJ, Haller D, Robles C, et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-Fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002; 21(A505).
60. Buyse M, Zeleniuch-Jaquitte A, Chalmers T. Adjuvant therapy of colorectal cancer-why we still don't know. JAMA 1988; 259:3571-8.
61. Moertel CG, Fleming TR, McDonald TS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-8. (Pubitemid 20042739)
62. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-326.
63. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer: Five-year final report of INT-0089. Proc Am Soc Clin Oncol 1998; 17:265a.
64. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from the National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-9. (Pubitemid 29517927)
65. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluoruracil in clinical practice: a population- based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20:3992-98.
66. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349-55. (Pubitemid 29220839)
67. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17:1356-63.
68. Marsoni S for IMPACT investigators. Efficacy of adjuvant fluorouracil and leucovorin in Stage B2 and C colon cancer. Semin Onocl 2001; 28 (suppl 1):14-19.
69. Piedbois P. Introduction, 4th International Conference on Colorectal Cancer in Paris. Semin Oncol 2001; 28 (suppl 1):1-3.
70. Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, et al. Comparative detection of lymph node microcetastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 2002; 20:4232-41. (Pubitemid 35191026)
71. Balzar M, Winter J, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999; 17:699-712.
72. Shen J-W, Atkinson B, Koprowski H, Sears HF. Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int J Cancer 1984; 33:465-8. (Pubitemid 14142422)
73. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monocolonal antibodies. Int J Cancer 1986; 38:47-53. (Pubitemid 16056257)
74. Shetye J, Frodin J-E, Christenssen B, Grant C, Jacobsson B, Sundelius S, et al. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monocolonal antibodies (Mab 17-1A). Cancer Immunol Immunother 1988; 27:154-62.
75. Goodwin RA, Tuttle SE, Bucci DM, Jewell SD, Martin EW, Steplewski Z. Tumor-associated antigen expression of primary and metastatic colorectal carcinomas detected by monoclonal antibody 17-1A. Am J Clin Pathol 1987; 88:462-7. (Pubitemid 17142214)
76. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cell lines. Science 1983; 221:865-7. (Pubitemid 13034288)
77. Liesveld JL, Frediani KE, Winslow JM, Duerst RE, Abboud CN. Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. J Cell Biochem 1991; 45:381-390.
78. Fogler WE, Kinger MR, Abraham KG, Gottlinger HG, Riethmuller G, Daddona PE. Enhanced cytotoxicity against colon carcinoma by combination of non-competing monoclonal antibodies to the 17-1A antigen. Cancer Res 1988; 48:6303-8.
79. Herlyn D, Sears H, Iliopoilos D, Lubeck M, Douillard JY, Sindelar W, et al. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma 1986; 5:S51-S58. (Pubitemid 16072918)
80. Fagerberg J, Hjelm A-L, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype reactive T-lymphocytes. Cancer Res 1995; 55:1824-7.
81. Riethmuller G, Scheider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancent 1994; 343:1177-83. (Pubitemid 24147551)
82. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for rectal Dukes's C colorectal carcinoma: Seven year outcome of a muticenter randomized trial. J Clin Oncol 1998; 16:1788-94.
83. Haller DG. Update of clinical trials with edrecolomab: A monoclonal antibody therapy for colorectal cancer. Semin Oncol 2001; 28 (suppl 1):25-30. (Pubitemid 32173101)
84. Punt CJ, Nagy J, Douillard A, Figer A, Skovsgaard T, Monson J, et al. Edrecolomab (17- 1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Pro Am Soc Clin Oncol 2001; 20:123a.
85. Fields AL, Keller AM, Schwartzberg L, Bernard S, Pazdur R, Kardinal C, et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study. Pro Am Soc Clin Oncol 2002; 21:128a.